AtaiBeckley Completes Redomiciliation from Netherlands to U.S.
AtaiBeckley announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company's extraordinary general meeting of shareholders on November 4, 2025. The redomiciliation was completed following the close of trading on the Nasdaq Global Market on December 30, 2025. At completion, all issued and outstanding ordinary shares of Atai Beckley N.V. were exchanged on a one-for-one basis for newly issued shares of common stock of the Delaware company, AtaiBeckley Inc. The former shareholders of Atai Beckley N.V. are now the stockholders of the Delaware company. AtaiBeckley Inc's common stock will continue to trade on NASDAQ under the trading symbol "ATAI".
Trade with 70% Backtested Accuracy
Analyst Views on ATAI
About ATAI
About the author

AtaiBeckley Provides 2026 Outlook with Accelerated Drug Development Plans
- Strategic Restructuring: AtaiBeckley enters 2026 with significant momentum following the merger of atai Life Sciences and Beckley Psytech and its redomiciliation to the U.S., which is expected to drive innovation in mental health treatments.
- Clinical Progress: BPL-003 demonstrated significant antidepressant effects in its Phase 2 trial for treatment-resistant depression, with plans to initiate a Phase 3 trial in Q2 2026, further validating its efficacy.
- Patent Protection: The new patent for EMP-01 was granted in December 2025, expected to provide market exclusivity until 2043, enhancing the company's competitive position in treating social anxiety disorder.
- Cost Savings: The completion of the redomiciliation from the Netherlands to the U.S. is anticipated to simplify corporate structure and reduce administrative burdens, thereby providing greater financial flexibility for future growth.

GH Research Secures FDA Clearance for GH001 Clinical Trial
- FDA Approval: The U.S. FDA lifted the clinical hold on GH Research Plc's GH001 trial, enabling the company to advance this potential ultra-rapid treatment for treatment-resistant depression, marking a significant milestone.
- Trial Progress: In February 2025, GH001's Phase 2b trial met its primary endpoint, demonstrating a significant reduction of 15.2 points in the Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 8, compared to a 0.3 point increase in the placebo group, indicating its strong antidepressant effect.
- Market Outlook: GH Research anticipates initiating its global pivotal program in 2026, with the CEO stating that discussions with the FDA will align the design for the Phase 3 trial, further propelling the product's market entry.
- Stock Reaction: GH Research shares surged 34.52% to $17.86 at the time of publication, reflecting positive market sentiment towards the FDA approval and optimistic expectations for future growth.






